Arbutus to participate in october investor conferences

Warminster, penn., sept. 28, 2021 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis b virus (hbv) infection, as well as therapies to treat coronaviruses (including covid-19), today announced that the company will participate in the following october investor conferences:
ABUS Ratings Summary
ABUS Quant Ranking